Medicare drug coverage costs more this year

Most seniors in Medicare's prescription-drug program are paying considerably higher monthly premiums this year, according to a new study; we'll have to wait and see whether the higher costs force seniors to drop coverage--and in turn, some of their prescription drugs. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.